News on technologies and applications for point-of-care testing.
This test is the firm's second assay on the point-of-care Accula molecular diagnostics system.
The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.
Through the Alnylam Act program, patients suspected of having the rare disease or with a family history of the illness will receive testing at no cost.
Under the deal, Novacyt's Primerdesign business will work with Applied Microarrays on the development of microarray-based diagnostic assays.
The university health system said that it reduced incorrectly prescribed antiviral prescriptions by almost 11 percent at the sites where it installed the Roche Cobas Liat PCR test platform.
